中国实验血液学杂志2024,Vol.32Issue(6) :1928-1932.DOI:10.19746/j.cnki.issn1009-2137.2024.06.045

单细胞测序技术在急性髓系白血病中的应用研究进展

Research Advance of Single Cell Sequencing Technology in Acute Myeloid Leukemia——Review

陈根旺 刘蕾 范春梅
中国实验血液学杂志2024,Vol.32Issue(6) :1928-1932.DOI:10.19746/j.cnki.issn1009-2137.2024.06.045

单细胞测序技术在急性髓系白血病中的应用研究进展

Research Advance of Single Cell Sequencing Technology in Acute Myeloid Leukemia——Review

陈根旺 1刘蕾 1范春梅1
扫码查看

作者信息

  • 1. 福建医科大学附属第二医院临床医学检验中心,福建泉州 362000
  • 折叠

摘要

急性髓系白血病(AML)是成人中最常见的具有高度异质性的急性白血病类型,尽管目前AML的预后风险分层和治疗方案不断得到优化,但总体长期生存率仍较低.单细胞测序技术(SCS)的出现在一定程度上解决了传统测序的缺陷,实现了对恶性肿瘤的研究由细胞群体向单个细胞层面的转变,因此已在多个生物学领域得到广泛应用.本文主要针对单细胞测序技术在分析AML的肿瘤异质性、疾病演变规律、肿瘤微环境的改变、耐药机制的阐明以及寻找潜在的治疗靶点等方面的应用进行综述.

Abstract

Acute myeloid leukemia (AML) is the most common and highly heterogeneous acute leukemia in adults. Despite the continuous optimization of prognostic risk stratification and treatment regimens,the overall long-term survival rate of AML patients remains low. The emergence of single cell sequencing (SCS) technology has overcome the defects of traditional sequencing to a certain extent,and realized the transformation of the research of malignant tumors from cell population level to single cell level. Consequently,it has been widely applied in many biological fields. This review mainly focuses on the application of SCS technology in the analysis of tumor heterogeneity,disease evolution,changes in tumor microenvironment,elucidation of drug resistance mechanisms and search for potential therapeutic targets in AML.

关键词

急性髓系白血病/单细胞测序技术/肿瘤内异质性/肿瘤微环境

Key words

acute myeloid leukemia/single cell sequencing technology/intratumour heterogeneity/tumor microenvironment

引用本文复制引用

出版年

2024
中国实验血液学杂志
中国病理生理学会

中国实验血液学杂志

CSTPCD北大核心
影响因子:0.988
ISSN:1009-2137
段落导航相关论文